|
Biological Activity
|
|
Description
|
E7080 (Lenvatinib) is a multi-target inhibitor of VEGFR2 and VEGFR3 with IC50 of 4 nM and 5.2 nM, respectively. |
|
Targets
|
VEGFR2 |
VEGFR3 |
VEGFR1 |
FGFR1 |
PDGFRα |
PDGFRβ |
|
IC50 |
4 nM |
5.2 nM |
22 nM [1] |
46 nM [1] |
51 nM [1] |
39 nM [1] |
|
In Vitro
|
E7080, as a potent inhibitor of in vitro angiogenesis, shows a significantly inhibitory effect on VEGF/KDR and SCF/Kit signaling. According to the in vitro receptor tyrosine and serine/threonine kinase assays, E7080 inhibits Flt-1, KDR, Flt-4 with IC50 of 22, 4.0 and 5.2 nM, respectively. In addition to these kinases, E7080 also inhibits FGFR1 and PDGFR tyrosine kinases with IC50 value of 46, 51 and 100 nM for FGFR1, PDGFRα and PDGFRβ, respectively. [1] E7080 potently inhibits phosphorylation of VEGFR2 (IC50, 0.83 nM) and VEGFR3 (IC50, 0.36 nM) in HUVECs which is stimulated by VEGF and VEGF-C, respectively. [2] A recent study shows that E7080 treatment (both at 1 μM and 10 μM) results in a significant inhibition of cell migration and invasion by inhibiting FGFR and PDGFR signaling. [3] |
|
In Vivo
|
When orally administrated in a H146 xenograft model, E7080 inhibits the growth of H146 tumor at 30 and 100 mg/kg in a dose-dependent manner and leads to tumor regression at 100 mg/kg. Furthermore, E7080 at 100 mg/kg decreases microvessel density more than anti-VEGF antibody and imatinib treatment. [1] E7080 significantly inhibits local tumor growth in a MDA-MB-231 mammary fat pad (m.f.p.) model with RTVs (calculated tumor volume on day 8/tumor volume on day 1) of 0.81, and reduces both angiogenesis and lymphangiogenesis of established metastatic nodules of MDA-MB-231 tumor in the lymph nodes. [2] |
|
Clinical Trials
|
E7080 is currently in Phase I clinical trials in patients with Refractory Solid Tumors Lymphomas. |
|
Features
|
|
|
Protocol
|
|
Cell Assay
[2]
|
| Cell Lines |
HUVECs |
| Concentrations |
0-10 μM |
| Incubation Time |
72 hours |
| Methods |
HUVECs (1,000 cells in each well in serum-free medium containing 2% fetal bovine serum) and L6 rat skeletal muscle myoblasts (5,000 cells in each well in serum-free DMEM) are dispensed in a 96-well plate and incubated overnight. E7080 and either VEGF (20 ng/mL) or FGF-2 (20 ng/mL) containing 2% fetal bovine serum and PDGFβ (40 ng/mL) are added to each well. Cells are incubated for 3 days and then the ratios of surviving cells are measured by WST-1 reagent. For proliferation assay, samples are duplicated and three separate experiments are done. |
|
Animal Study
[1]
|
| Animal Models |
H146 tumor cells are implanted subcutaneously (s.c.) into the flank region of female BALB/c nude mice. |
| Formulation |
E7080 is dissolved in suspended in 0.5% methylcellulose. |
| Doses |
≤100 mg/kg |
| Administration |
Administered via p.o. |
|